Bausch Health Beats Q1 Estimates Driven by Strong Segment Growth

Bausch Health Companies (NYSE: BHC) began its 2026 fiscal year with a positive performance, delivering first-quarter results that topped analyst expectations on both the top and bottom lines. Following the announcement, the company's stock rose nearly 2% week-to-date. The growth was broad-based across the company's diversified portfolio. Total revenue for the period reached $2.52 billion, a 12% increase year-over-year, surpassing the consensus estimate of $2.42 billion. On the bottom line, non-GAAP net income rose 35% to $296 million, resulting in earnings of $0.78 per share, beating the projected $0.68 per share. Performance was led by the Bausch + Lomb eyecare business, which generated $1.24 billion in revenue, a 9% increase. Other segments showed even more aggressive growth, with the Salix and Solta Medical divisions increasing their revenue by 18% and 51%, respectively. Looking forward, Bausch Health maintained its full-year 2026 revenue guidance, forecasting between $10.67 billion and $10.92 billion. The company also projected adjusted EBITDA in the range of $3.89 billion to $4.01 billion. Management highlighted a strategic focus on its pipeline, specifically the advancement of the investigational hepatitis drug larsucosterol, while remaining open to business development opportunities aligned with its strategic priorities.